🇺🇸 FDA
Pipeline program

Teduglutide

CL0600-017

Phase 1 small_molecule completed

Quick answer

Teduglutide for Hepatic Impairment is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hepatic Impairment
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials